Longeveron Rallies 20% In Morning Trade

On:

Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.

Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).

The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.

LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Bitcoin At Risk Of 50% Drop Before Next Halving If Historical Trend Repeats, Warns Influential Crypto Guru
  2. Can Next Bitcoin Halving Push BTC Price To $148,000 By July 2025? Pantera Capital Thinks So
  3. Markets Begin The Week On A Sober Note; Await The Fed’s Decision
  4. Insignia Systems Shares Rise In Morning Trade
  5. Bitcoin Miners Dump $55 Million Worth of $BTC Amid Price Drop to Key Support Level